PQR-309 is primarily used as a dual inhibitor targeting PI3K and mTOR signaling pathways, making it a valuable compound in oncology research. It is investigated for its potential in treating various cancers, particularly those with dysregulated PI3K/mTOR activity such as breast cancer, lymphoma, and glioblastoma. Due to its ability to cross the blood-brain barrier, PQR-309 shows enhanced efficacy in preclinical models of brain tumors compared to other inhibitors in its class. It is also studied in combination therapies to overcome resistance to conventional chemotherapeutic agents. Its balanced potency against both PI3K and mTOR reduces feedback activation commonly seen with selective inhibitors, improving antitumor activity in solid and hematological malignancies.